human
infect
novel
coronaviru
first
identifi
via
syndrom
surveil
decemb
wuhan
china
sinc
identif
infect
coronaviru
caus
novel
pathogen
spread
global
confirm
case
march
openlabel
clinic
trial
conclud
suggest
improv
resolut
viremia
use
two
exist
therapi
hydroxychloroquin
hcq
monotherapi
combin
azithromycin
hcqaz
result
import
trial
major
implic
global
polici
rapid
scaleup
respons
pandem
author
present
result
pvalu
differ
proport
studi
arm
analysi
abl
provid
effect
size
estim
address
gap
modern
analyt
method
includ
surviv
model
appli
data
show
modest
impact
hcq
treatment
signific
effect
hcqaz
combin
potenti
suggest
role
coinfect
pathogenesi
trial
gautret
colleagu
consider
effect
size
pvalu
multipl
model
provid
suffici
evid
support
widescal
rollout
hcq
monotherapi
treatment
larger
random
studi
consid
data
also
suggest
randomizedcontrol
studi
hcqaz
combin
therapi
undertaken
evidencebas
public
health
program
essenti
global
pandem
plan
optim
resourc
howev
unadjust
analys
may
provid
distort
estim
full
util
scarc
clinic
data
especi
consider
intentiontotreat
analys
person
enrol
analys
final
effect
size
estim
allow
magnitud
potenti
clinic
impact
consid
polici
adopt
statist
signific
may
biolog
import
analys
perform
use
stata
colleg
station
tx
usa
standard
confid
interv
use
model
parsimoni
assess
use
akaik
bayesian
inform
criteria
aicbic
model
adjust
age
sex
assess
predict
power
logist
model
use
tjur
data
obtain
supplement
tabl
digit
use
tabula
softwar
subsequ
handvalid
data
six
patient
losttofollowup
ltf
manual
enter
databas
primari
outcom
report
author
primari
endpoint
virolog
clearanc
postinclus
optim
analysi
endpoint
binari
regress
avoid
mani
potenti
bias
logist
model
outcom
common
state
secondari
endpoint
virolog
clearanc
overtim
studi
period
standard
cox
surviv
time
model
roystonparmar
flexibl
parameter
model
use
captur
timetofirst
neg
pcr
ct
threshold
incorpor
censor
patient
per
standard
method
sequenc
confirm
viremia
via
pcr
shown
fig
lft
patient
bottom
figur
primari
outcom
assess
use
binari
regress
provid
rel
risk
clearanc
viremia
studi
arm
main
effect
interest
combin
hcqtreat
patient
versu
control
show
margin
signific
risk
ratio
ci
p
analysi
separ
hcq
hcqaz
outcom
possibl
due
quasisepar
model
address
limit
model
firth
penalizedlikelihood
model
use
deal
well
separ
quasisepar
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
assess
secondari
outcom
kaplanmei
cox
model
use
initi
compar
timetoev
adjust
covari
due
sever
proport
hazard
violat
hcqaz
group
flexibl
parametr
model
use
estim
effect
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
togeth
result
especi
consider
loss
followup
six
patient
provid
suffici
evid
support
hcq
monotherapi
treatment
analysi
without
limit
interpret
present
dataset
may
incorrect
analysi
model
primari
secondari
outcom
endpoint
infer
origin
author
descript
power
calcualt
casecontrol
design
covari
avail
origin
data
howev
taken
togeth
analysi
suggest
studi
hcqaz
combin
therapi
priorit
great
hast
rapid
increas
confirm
infect
within
last
day
suggest
pandem
acceler
major
opportun
cost
associ
choic
rapid
scienc
critic
progress
ccbi
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
